» Articles » PMID: 19644403

Etiology and Clinical Course of Febrile Neutropenia in Children with Cancer

Overview
Specialty Pediatrics
Date 2009 Aug 1
PMID 19644403
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The etiology, clinical course, and outcome of fever and neutropenia (FN) in children with cancer using the current FN guidelines and diagnostic resources in the United States have not been well described.

Patients And Methods: Medical records of a randomly selected FN episode per patient during 2004-2005 at a pediatric oncology center were reviewed. Patients were managed as per institutional FN guidelines and blood cultures collected in continuously read BACTEC bottles.

Results: Of 337 FN episodes, infection was proven in 86 (25%) and probable in 75 (22%). In all, 177 episodes (53%) were judged fever of unknown origin (FUO). Bacteremia accounted for most (41) of the proven bacterial episodes, with viridans streptococci (13), Pseudomonas spp. (6) and Escherichia coli (6) the most frequently isolated organisms. The median time to positivity of blood cultures was 12 hours (range, 5.4-143.7) with 93% positive within 24 hours of incubation. Viral pathogens were identified in 29 (34%) episodes. Compared with other patients, those with FUO had shorter median duration of fever (0.5 vs. 2.0 d; P<0.0001) and hospitalization (3 vs. 6 d; P<0.0001), longer median duration since last chemotherapy (6.0 vs. 4.0 d; P=0.01), and were less likely to have a diagnosis of acute myelogenous leukemia (11% vs. 22%; P=0.009) or develop a clinical complication (5.1% vs. 24.4%; P<0.0001).

Conclusions: Despite currently available diagnostic resources, the majority of patients with FN have FUO marked by a low rate of clinical complications and no infection-related mortality. Emergence of viridans streptococci as the most common blood isolate has affected FN treatment recommendations. Study findings will help further development of strategies for risk stratified management of fever with neutropenia in pediatric patients.

Citing Articles

Clinical Outcomes and Determinants of Survival in Patients with Hematologic Malignancies Admitted to Intensive Care Units with Critical Illness.

Singh S, Sharma R, Singh J, Jain K, Kaur G, Gupta V Indian J Hematol Blood Transfus. 2024; 40(3):423-431.

PMID: 39011248 PMC: 11246339. DOI: 10.1007/s12288-024-01757-3.


Microbiological Spectrum of Neutropenic Sepsis in Cancer Patients Admitted to a Tertiary Health Care Centre.

John K, Warrier A, Warrier A Cureus. 2023; 15(8):e43898.

PMID: 37746392 PMC: 10515477. DOI: 10.7759/cureus.43898.


Etiology and Factors Affecting Severe Complications and Mortality of Febrile Neutropenia in Children with Acute Leukemia.

Erbas I, Cakil Guzin A, Ozdem Alatas S, Karaoglu Asrak H, Akans I, Akyol S Turk J Haematol. 2023; 40(3):143-153.

PMID: 37525503 PMC: 10476243. DOI: 10.4274/tjh.galenos.2023.2023.0185.


Characterization of Febrile Neutropenia Management in Children With Malignancies: A Single-Center Evaluation.

Khairullah A, Garner L, DeMarco M, Wilson W J Pediatr Pharmacol Ther. 2023; 28(3):235-240.

PMID: 37303769 PMC: 10249966. DOI: 10.5863/1551-6776-28.3.235.


The role of presepsin in pediatric patients with oncological and hematological diseases experiencing febrile neutropenia.

Cerasi S, Leardini D, Lisanti N, Belotti T, Pierantoni L, Zama D Sci Rep. 2023; 13(1):6464.

PMID: 37081067 PMC: 10119114. DOI: 10.1038/s41598-023-33094-2.


References
1.
Ariffin H, Navaratnam P, Lin H . Surveillance study of bacteraemic episodes in febrile neutropenic children. Int J Clin Pract. 2002; 56(4):237-40. View

2.
Velasco E, Byington R, Martins C, Schirmer M, Dias L, Goncalves V . Bloodstream infection surveillance in a cancer centre: a prospective look at clinical microbiology aspects. Clin Microbiol Infect. 2004; 10(6):542-9. DOI: 10.1111/j.1469-0691.2004.00874.x. View

3.
Rondinelli P, Ribeiro K, de Camargo B . A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. J Pediatr Hematol Oncol. 2006; 28(10):665-70. DOI: 10.1097/01.mph.0000212996.94929.0b. View

4.
Ascioglu S, Rex J, De Pauw B, Bennett J, Bille J, Crokaert F . Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2001; 34(1):7-14. DOI: 10.1086/323335. View

5.
Yadegarynia D, Tarrand J, Raad I, Rolston K . Current spectrum of bacterial infections in patients with cancer. Clin Infect Dis. 2003; 37(8):1144-5. DOI: 10.1086/378305. View